De novo formation of tertiary lymphoid structures (TLS) has been described in lung cancers. Intra-tumoral TLS appear to be functional and are associated with a longterm survival for lung cancer patients, suggesting that they represent an activation site for tumor-specific T cells. Here, we characterized T cell recruitment to TLS in human lung cancer in order to identify the adhesion molecules and chemoattractants orchestrating this migration. We found that most TLS T cells were CD62L+ and mainly of CD4+ memory phenotype, but naïve T cells were highly enriched in these structures as compared to the rest of the tumor. A specific gene expression signature associated with T cell presence was identified in TLS, which included chemokines (CCL19, CCL21, CXCL13, CCL17, CCL22, IL16), adhesion molecules (ICAM-2, ICAM-3, VCAM-1, MAdCAM-1) and integrins (alphaL, alpha4, alphaD). The presence of the corresponding receptors on TLS T cells was confirmed. Intra-tumoral PNAd+ high endothelial venules also were exclusively associated with TLS and co-localized with CD62L+ lymphocytes. Together, these data bring new insights into the T-cell recruitment to intra-tumoral TLS and suggest that blood T cell enter into TLS via high endothelial venules, which represent a new gateway for T cells to the tumor. Findings identify the molecules that mediate migration of tumor-specific T cells into tertiary lymphoid structures where T cell priming occurs, suggesting new strategies to enhance the efficacy of cancer immunotherapies.
Introduction
The tumor microenvironment is a complex network of different cell types which include cells of the immune system, interspersed with blood and lymphatic vessels. A large body of evidence demonstrates that the local density of tumor-infiltrating T cells influences the clinical outcome of the patients (1, 2) . The presence of such cells in the tumor microenvironment prompts the question of where and how these T cells are recruited and activated.
Transendothelial migration of lymphocytes to tissues is dependent on a molecular signaling interplay between endocytes and lymphocytes (3) . Indeed, recruitment of blood T cells in lymph nodes is well characterized and depends on a specific set of adhesion molecules including CD62L and the chemokines CCL19-CCL21 (T cell zone) and CXCL13 (B cell follicles) together with their receptors, CCR7 and CXCR5 respectively (reviewed in references 4 and 5). Blood and lymphatic vessels are present in the tumor microenvironment, however, the molecules which orchestrate T cell entry and trafficking in human cancer are still poorly defined.
We have reported the presence of Tertiary Lymphoid Structures (TLS) in the tumor stroma in Non-Small Cell Lung Cancer (NSCLC) (6) . These structures have been described in many human pathologies, such as auto-immune diseases, infections, or rejection of organ transplants (7) (8) (9) . They are immunologically functional, and have been linked to the local development of cellular and humoral immune responses, using mouse models (10, 11) .
In lung cancers, the intra-tumoral TLS exhibit functional features with clusters of mature Dendritic Cells (DC) and T cells adjacent to B cell follicles which contain proliferating germinal centers (6) . As they resemble BALT (Bronchus-Associated Lymphoid Tissue) and were not found in non-tumoral tissues, these follicles were termed Ti-BALT, for Tumor-induced BALT. We demonstrated for the first time a longterm survival in patients with a high density of Ti-BALT (6) , suggesting that these structures could be a site of induction of anti-tumoral responses. The good prognostic value of both Ti-BALT and T cell densities (1) in cancer patients prompted us to investigate the role of Ti-BALT in T cell recruitment. Using combined laser microdissection, Q-PCR, immunohistochemistry and flow cytometry, we identify a set of integrins, adhesion molecules and chemokines expressed in Ti-BALT and associated with T lymphocyte presence. These data give new insights into T-cell recruitment into cancer TLS, that help to understand their organization and prognostic value. 
Materials and methods

Patients
Immunohistochemistry and immmunofluorescence
Serial 5µm tissue sections of paraffin-embedded lung tumors were deparaffinized, rehydrated, and pretreated in appropriate buffer for antigen retrieval (see Appendix   Table A2 ). Then, the sections were incubated with 5% human serum for 30 min before adding the appropriate antibodies or isotype controls (see Appendix Table   A2 ). Enzymatic activity was revealed as described previously (6) . When necessary, sections were counterstained with hematoxylin. Images were acquired using a Nikon Eclipse 80i microscope (Nikon, Champigny-sur-Marne, France) operated with Nikon NIS Elements BR software. Immunofluorescent staining were read on a Zeiss LSM 700 confocal microscope with the Zen software (Zeiss, Oberkochen, Germany). 
Enrichment of tumor-infiltrating lymphocytes
Fresh lung tumor specimens were mechanically dissociated and incubated in a nonenzymatic solution (Cell Recovery solution, BD Biosciences, Le Pont-de-Claix, France) for 1h at 4°C. The cell suspension was then filtrated through a 70µm filter (BD Biosciences), and the mononuclear cells were isolated by centrifugation over Ficoll Hypaque.
Flow cytometry
Multiple stainings were performed using antibodies against chemokine receptors, anti-CD3 anti-CD4, anti-CD8, anti-CD45RA, anti-CD45RO, anti-CD62L (see Appendix Table A2 ). Briefly, after saturation with 2% human serum, mononuclear cells were incubated with the primary antibodies or appropriate isotype controls for 30 min at +4°C in the dark. Then, cells were washed and fixed in 1% formaldehyde before the analysis on a LSRII cytometer (BD Biosciences). Flow cytometry data were analyzed with the Diva software (BD Biosciences).
Laser-microdissection
Tumor sections of 14 µm were cut at -20°C and mounted on PEN slide (Leica).
Tissue sections were stained in RNAse-free 0.01% toluidin blue for 2 min, dehydrated in xylene 100% and air-dried. Once dry, laser microdissection was performed using a laser capture microscope (AS LMD, Leica). The microdissected 
RESULTS
Ti-BALT T cells are mainly CD4+ memory T cells and most naïve T cells home into
Ti-BALT
In order to study the recruitment of T cells into Ti-BALT, we first characterized T cell subpopulations present in Ti-BALT by confocal microscopy on 15 Ti-BALT from 3 different paraffin-embedded tumors. We observed that Ti-BALT T cells contained both CD4+ and CD8+ T cell subsets (Fig. 1A) , with a clear predominance of CD4+ T cells (88±4 % of CD4+ T cells versus 12±4% of CD8+ T cells) (Fig. 1B) . On the contrary, CD8+ T cells were largely predominant outside Ti-BALT (data not shown).
We then assessed the stage of differentiation of Ti-BALT T cells using CD45RA and CD45RO markers (Fig. 1C-D) . We found that most Ti-BALT T cells have a memory phenotype (66±7% of CD45RO+ T cells versus 34±7% of CD45RA+ naïve T cells) (Fig. 1C) . However, naïve CD45RA+ T cells were very rarely seen in the other areas of the tumor (data not shown), suggesting that they preferentially localize inside Ti-
BALT.
The adhesion molecule CD62L is a lymphoid homing molecule known to be expressed by both naïve and central-memory T cells. We thus investigated its expression on Ti-BALT T cells by immunohistochemistry, and observed that the vast majority of Ti-BALT cells are positive for CD62L (Fig. 1E) . In contrast, no CD62L positive cell could be detected outside the Ti-BALT. To further demonstrate these findings, we showed by confocal microscopy that CD62L is actually expressed on Ti-BALT T cells (Fig. 1F ), whereas it is not expressed on T cells located outside these lymphoid structures (Fig. 1G ). Thus, we used CD62L as a Ti-BALT T cell marker for flow cytometry experiments.
Using Tumor-Infiltrating Lymphocytes (TIL) isolated from fresh tumor samples, we confirmed that the main subpopulation of Ti-BALT T cells is CD4+ memory T cells (55±10% of total CD3+ CD62L+ T cells), followed by CD8+ naïve T cells (22±10% of CD3+ CD62L+ T cells) and then CD8+ memory T cells and CD4+ naïve T cells (11% and 9% of total Ti-BALT T cells, respectively) ( Fig. 2A) .
In order to determine the predominant localization of the main T cell subsets in the tumor, we calculated the ratio of CD62L+/total T cells for each subset (Fig. 2B ). In line with results described above, we found that Ti-BALT are highly enriched in CD4+ CD45RA+ naïve T cells (n-fold=4.3 ; p=0.0009). The CD4+ CD45RO+ memory T cells (n-fold=1.7 ; p=0.0025) and the CD8+ CD45RA+ naïve T cells (n-fold=2.3; p=0.08) home also preferentially in Ti-BALT (n-fold=1.7 ; p=0.0025). In contrast, CD8+ CD45RO+ memory T cells were located mainly outside the Ti-BALT (nfold=3.9 ; p =0.0002).
Altogether, these data clearly demonstrate a selective T cell distribution within the Ti-BALT with a majority of CD4 memory T cells, and a preferential homing of naïve T cells.
Identification of a chemokine and adhesion molecule signature in Ti-BALT, and correlation with CD3 expression
The selective T cell distribution described above prompted us to investigate the expression of homing molecules associated with Ti-BALT T cell presence. This was performed by a laser micro-dissection approach of both Ti-BALT and tumor nest (Fig. 3A) and chemoattractants, including all known chemokines ( Fig. 3B and 3C ). The relative quantification of these genes normalized to beta-actin is presented in Appendix Figure A4 . We then constructed a correlation matrix of gene expression that we submitted to hierarchical clustering (Fig. 3D) . This allowed us to determine two major clusters of genes displaying similar correlation profile. One cluster contained genes co-regulated with Ep-CAM (black rectangle), and thus associated with tumor cell density. The other one contained genes co-regulated with CD3ε (red rectangle), and thus associated with T cell density. We thus identified by differential gene expression, a network of intercorrelated genes associated with T cell presence in Ti-BALT (Table 1) which are likely involved in T cell recruitment to these lymphoid structures.
Proteic expression of a set of chemoattractants in Ti-BALT and their counterparts by
Ti-BALT T cells
To confirm the potential role of the chemoattractant genes found above, we investigated their proteic expression on tumor sections (Fig. 4-5) . The lymphoid chemokines CCL19, CCL21 and CXCL13 displayed significant expression in Ti-BALT whereas they were not expressed in tumor islets (data not shown). The CCL19 positive cells were located in the extrafollicular areas of Ti-BALT ( restricted to lymphatic vessels (Fig. 4B ) positive for podoplanin (Fig. 4C-D) . CXCL13 was strongly expressed in the germinal centers (Fig. 4E ) by CD21+ FDC (Fig.5B) . IL-16 was expressed by most Ti-BALT lymphocytes (Fig. 4F) , whereas CCL22 and CCL17 were observed in the Ti-BALT periphery ( Fig. 4G and 4H , respectively) on CD138+ plasma cells (Fig. 5C and 5D, respectively) . These results demonstrate that the chemoattractants associated with CD3 expression are actually produced inside the Ti-BALT. We then assessed the expression of all chemokine receptors (CKR) by flow cytometry and confirmed that all receptors of chemokines locally produced are significantly expressed on both CD4+ and CD8+ TIL (Appendix Fig. A5 ).
Furthermore, all chemoattractants receptors associated with T cell presence in Ti-BALT were expressed in a significantly greater proportion of Ti-BALT T cells as compared to non Ti-BALT T cells (Fig. 5E ). Altogether these data provide strong arguments in favor of a role of these chemoattractants in the active recruitment of T cell subsets to the Ti-BALT.
HEV co-localize with Ti-BALT, and express adhesion molecules strongly associated with T cell recruitment to Ti-BALT
Having demonstrated that Ti-BALT T cells selectively express CD62L, we investigated whether lung tumors contain HEV, specialized vessels expressing the CD62L ligand PNAd. We found presence of PNAd+ HEV in tumors, exclusively associated with Ti-BALT (Fig. 6A) , as they were never observed independently of these lymphoid structures and strictly co-localized with CD62L+ cells (Fig. 6B) . The HEV seemed functional as red blood cells could readily be seen in the lumen of the venules (Fig. 6B, insert) . 
To further investigate HEV potential role in lymphocyte recruitment, we analyzed the in situ expression of adhesion molecules known to interact with the integrins alpha chains related to T cell infiltration (alphaL, alphaD and alpha4, see Table 1 ). As illustrated in Figure 6 , we observed that PNAd + HEV were positive for ICAM-2 ( Fig.   6C ), ICAM-3 (Fig. 6D) , VCAM-1 (Fig. 6E) , and MAdCAM-1 (Fig. 6F) .
Altogether, these data strongly argue for a crucial role of HEV and CD62L/PNAd ligand/receptor pair in lymphocyte recruitment to the Ti-BALT. 
Discussion
A series of lines of evidence suggests that the recruitment of T cells to tumors occurs through intra-tumoral blood vessels and depends on inflammatory chemokines (13) .
For the first time we identified a set of molecules associated with T cells in intratumoral TLS. We also report the presence of PNAd+ HEV specifically associated with the Ti-BALT.
PNAd+ HEV allow the recruitment of both naïve and central-memory CD62L+ T cells in lymph node (4) . Here, we report that CD62L expression is exclusively found on Ti-BALT T cells while PNAd+ HEV were systematically associated with TLS in tumor stroma. This argues strongly that CD62L/PNAd molecules play a similar role in lymphocyte HEV-mediated recruitment in human cancer-associated TLS.
We have also shown the expression of a set of chemoattractants (CCL17, CCL19, BALT. Furthermore, it has recently been shown that DC plays an essential role in pulmonary TLS maintenance (16, 17) . Since mature DC in human are known to secrete CCL19 (18) , these data suggest that this cytokine could play a role not only in T cell recruitment but also in Ti-BALT maintenance.
Expression of CCR4 and its ligands CCL17 and CCL22 was found in Ti-BALT at the mRNA and protein levels. The CCL17 and CCL22 chemokines have been shown to recruit effector T cells (19) (20) (21) (22) , as well as regulatory T cells (Treg) (22) (23) (24) (25) in cancer mouse models. The ambivalent role of these chemokines is confirmed by the fact that CCL22 has been associated with tumor regression in mouse models (20, 21, 26) and good prognosis in human lung cancer (27) whereas its expression correlates with Treg infiltration and poor prognosis in breast cancer (23) . Since many Ti-BALT T cells express CCR4, and Ti-BALT contains very few Treg (data not shown), we hypothesize that this receptor would recruit mostly other T cell subtypes in these structures.
Finally, the presence of IL-16 has never been reported in cancer or in TLS. Its chemoattractive role for CD4+ T cells and DC is well known (28) , and it has been shown to be involved in T cell recruitment in the pancreas of NOD mice (29) . These data as well as the preferential localization of CD4+ T cell and DC populations in the Ti-BALT are good arguments for a direct role of this cytokine in T cell recruitment in these lymphoid structures.
The association between Ti-BALT and patient survival described previously (6) suggest a role of these structures in anti-tumoral responses. A possible mechanism sustaining this effect could be the recruitment of T cells via the set of chemoattractants and adhesion molecules described above followed by the However, the fact that lymphatic vessel density is associated with lymph node invasion in most cancers (36) suggests that at least a part of intra-tumoral lymphatic vessels can function as efferent. We thus propose that the central memory T cells CCL21+ lymphatic vessels and reach the draining lymph nodes to establish a systemic memory response (Appendix Fig. A6 ).
Our data argues strongly for a participation of several adhesion molecules and chemokines in T cell recruitment to intra-tumoral TLS in NSCLC, some of them being identical to those implied in constitutive lymph node homing. It has been described that T cell-based immunotherapy regimens suffered from inadequate homing of injected T cells to tumor tissue (37) . Therefore these data could be relevant for designing immunotherapy strategies targeting T cell to the tumor and should be tested accordingly in relevant preclinicals models. 
